FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

6 results

dabigatran
(DABIGATRAN ETEXILATE)
AvKARE
Usage: Dabigatran etexilate is indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism, preventing recurrence of these conditions, and for prophylaxis after hip replacement surgery in adult patients.
dabigatran etexilate
(Dabigatran Etexilate)
Alembic Pharmaceuticals Limited
Usage: Dabigatran etexilate is indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism after parenteral anticoagulant use, preventing recurrence of these conditions, and providing prophylaxis following hip replacement surgery in adults.
eliquis
(apixaban)
E.R. Squibb & Sons, L.L.C.
Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.
pradaxa
(dabigatran etexilate mesylate)
Boehringer Ingelheim Pharmaceuticals Inc.
Usage: PRADAXA Capsules are indicated for reducing the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism in adults, prophylaxis post-hip replacement surgery, and treating and preventing venous thromboembolic events in pediatric patients aged 8 to less than 18 years.
savaysa
(EDOXABAN TOSYLATE)
Daiichi Sankyo Inc.
Usage: SAVAYSA is indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for treating deep vein thrombosis and pulmonary embolism after initial therapy with a parenteral anticoagulant. It should not be used in patients with CrCL > 95 mL/min.
xarelto
(rivaroxaban)
Janssen Pharmaceuticals, Inc.
Usage: XARELTO is indicated for reducing the risk of stroke in nonvalvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), preventing DVT after hip or knee replacement, and reducing major cardiovascular events in coronary artery disease. It's also used in pediatric patients for VTE treatment and prevention.

Medications for Nonvalvular Atrial Fibrillation

dabigatran

dabigatran etexilate

eliquis

pradaxa

savaysa

xarelto